Canada markets close in 5 hours 3 minutes
  • S&P/TSX

    19,584.58
    -84.59 (-0.43%)
     
  • S&P 500

    4,124.10
    -15.96 (-0.39%)
     
  • DOW

    32,791.98
    -40.56 (-0.12%)
     
  • CAD/USD

    0.7768
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    91.77
    +1.01 (+1.11%)
     
  • BTC-CAD

    29,755.29
    -1,512.53 (-4.84%)
     
  • CMC Crypto 200

    536.32
    -21.03 (-3.77%)
     
  • GOLD FUTURES

    1,811.50
    +6.30 (+0.35%)
     
  • RUSSELL 2000

    1,916.72
    -24.49 (-1.26%)
     
  • 10-Yr Bond

    2.7880
    +0.0230 (+0.83%)
     
  • NASDAQ

    12,496.90
    -147.56 (-1.17%)
     
  • VOLATILITY

    21.86
    +0.57 (+2.68%)
     
  • FTSE

    7,494.27
    +11.90 (+0.16%)
     
  • NIKKEI 225

    27,999.96
    -249.28 (-0.88%)
     
  • CAD/EUR

    0.7595
    -0.0031 (-0.41%)
     

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
ProQR Therapeutics N.V.
ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S.

ProQR presentation

Presentation title: Development of RNA Base Editing Technologies for Precision Medicines
Presenter: Gerard Platenburg, Co-Founder and Chief Innovation Officer at ProQR
Presentation type: Oral presentation
Session: Oligonucleotide Discovery, Preclinical and Clinical
Date: May 11, 2022 at 11:15am EDT

About Axiomer® Technology

ProQR is pioneering a next-generation RNA base editing technology called Axiomer®, which could potentially yield a new class of medicines for genetic diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells. The Axiomer® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR (Adenosine Deaminase Acting on RNA), which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G).

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for genetic diseases. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference and the potential of our technologies and platforms (including Axiomer®). Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com

Media Contact:
Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
robert.stanislaro@fticonsulting.com



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting